Human iPSC-Derived Cerebral Organoid Differentiation Kit

产品示意（Product Diagram）

Protocol Diagram of cerebral organoid differentiation.

Orgnaoid Histology

Left: Early-stage cerebral organoid show rosette-like structures (neural stem cells), which become smaller as organoids develop.
Right: Day 109 cerebral organoids show uniform morphology and show no dead core inside.

Marker Expression

Presence of TH and MAP2 positive neurons in day 92 cerebral organoid.
TH: used as cell marker of dopaminergic neurons.
MAP2: mature neuron cell marker.

Left: Presence of GFAP positive cells at day 109 cultured cerebral organoid.
Right: Presence of OLIG2 positive cells at day 119 cultured cerebral organoid.
GFAP: marker for astrocyte.
OLIG2: marker for oligodendrocyte.

Presence of TH and IBA1 positive cell in day 147 cultured cerebral organoid.
IBA1: cell marker for microglia.

Organoid Activity

A: patch-clamp recording of excitatory neurons sectioned from cerebral organoids at day 102. Excitatory neuron showed stable response to step injection currents.
B: Recording of cerebral organoid (day 60) using silicon probe. Neurons showed spontaneous activities and different waveforms.
C: MEA recording indicated spontaneous bursting activities for cerebral organoid (day 86).

Organoid Application

Using cerebral organoids for modelling Parkinson's Disease. Cerebral organoids are treated with Human Alpha-Synuclein Pre-formed Fibrils Protein. Dopaminergic neurons and MAP2 positive neurons are damaged with both 0.1 μM and 1 μM Alpha-Synuclein Pre-formed Fibrils.

AAVs selection using cerebral organoids: Different capsid of AAVs were incubated with cerebral organoids. As the results, different affinities of each AAV to the cerebral organoid were observed.